{"id":"https://openalex.org/W4416634994","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2461","title":"General physicians\u2019 experience and perception of symptoms control in patients of asthma changed to branded generic formulation of Salmeterol/Fluticasone in Spain: The ORIGEN study","display_name":"General physicians\u2019 experience and perception of symptoms control in patients of asthma changed to branded generic formulation of Salmeterol/Fluticasone in Spain: The ORIGEN study","publication_year":2025,"publication_date":"2025-09-27","ids":{"openalex":"https://openalex.org/W4416634994","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2461"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2025.pa2461","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2461","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa2461","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Jorge R\u00e1bago Castro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165557","display_name":"Hospital Universitario Infanta Leonor","ror":"https://ror.org/05nfzf209","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210165557"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jorge R\u00e1bago Castro","raw_affiliation_strings":["1Hospital Infanta Leonor, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Hospital Infanta Leonor, Madrid, Spain","institution_ids":["https://openalex.org/I4210165557"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088494723","display_name":"Bel\u00e9n L\u00f3pez-Mu\u00f1iz Ballesteros","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165557","display_name":"Hospital Universitario Infanta Leonor","ror":"https://ror.org/05nfzf209","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210165557"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Belen L\u00f3pez-Mu\u00f1iz Ballesteros","raw_affiliation_strings":["1Hospital Infanta Leonor, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Hospital Infanta Leonor, Madrid, Spain","institution_ids":["https://openalex.org/I4210165557"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Aniruddha Mukhopadhyay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133301","display_name":"Cipla (India)","ror":"https://ror.org/02w6dqa48","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210133301"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Aniruddha Mukhopadhyay","raw_affiliation_strings":["2Global Medical Affairs, Cipla Ltd, Mumbai (Maharashtra), India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Global Medical Affairs, Cipla Ltd, Mumbai (Maharashtra), India","institution_ids":["https://openalex.org/I4210133301"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057002220","display_name":"Abhijit Vaidya","orcid":"https://orcid.org/0000-0002-6046-9105","observed_orcids":["https://orcid.org/0000-0002-6046-9105"]},"institutions":[{"id":"https://openalex.org/I4210133301","display_name":"Cipla (India)","ror":"https://ror.org/02w6dqa48","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210133301"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Abhijit Vaidya","raw_affiliation_strings":["3Clinical Trials, Medical Services, Cipla Ltd, Mumbai (Maharashtra), India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Clinical Trials, Medical Services, Cipla Ltd, Mumbai (Maharashtra), India","institution_ids":["https://openalex.org/I4210133301"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071633194","display_name":"Sushmeeta Chhowala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133301","display_name":"Cipla (India)","ror":"https://ror.org/02w6dqa48","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210133301"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Sushmeeta Chhowala","raw_affiliation_strings":["3Clinical Trials, Medical Services, Cipla Ltd, Mumbai (Maharashtra), India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Clinical Trials, Medical Services, Cipla Ltd, Mumbai (Maharashtra), India","institution_ids":["https://openalex.org/I4210133301"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109976104","display_name":"Jaideep A. Gogtay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133301","display_name":"Cipla (India)","ror":"https://ror.org/02w6dqa48","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210133301"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Jaideep Gogtay","raw_affiliation_strings":["2Global Medical Affairs, Cipla Ltd, Mumbai (Maharashtra), India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Global Medical Affairs, Cipla Ltd, Mumbai (Maharashtra), India","institution_ids":["https://openalex.org/I4210133301"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078000430","display_name":"Vaibhav Gaur","orcid":"https://orcid.org/0000-0002-6151-7770","observed_orcids":["https://orcid.org/0000-0002-6151-7770"]},"institutions":[{"id":"https://openalex.org/I4210133301","display_name":"Cipla (India)","ror":"https://ror.org/02w6dqa48","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210133301"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Vaibhav Gaur","raw_affiliation_strings":["2Global Medical Affairs, Cipla Ltd, Mumbai (Maharashtra), India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Global Medical Affairs, Cipla Ltd, Mumbai (Maharashtra), India","institution_ids":["https://openalex.org/I4210133301"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA2461","last_page":"PA2461"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9320999979972839,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9320999979972839,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.03310000151395798,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.006099999882280827,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/asthma","display_name":"asthma","score":0.9319999814033508},{"id":"https://openalex.org/keywords/salmeterol-fluticasone","display_name":"salmeterol/fluticasone","score":0.953000009059906},{"id":"https://openalex.org/keywords/generic-drug-switching","display_name":"generic drug switching","score":0.6420000195503235},{"id":"https://openalex.org/keywords/symptom-management","display_name":"symptom management","score":0.6389999985694885},{"id":"https://openalex.org/keywords/treatment-switching","display_name":"treatment switching","score":0.33799999952316284},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.7590000033378601},{"id":"https://openalex.org/keywords/asthma-exacerbations","display_name":"asthma exacerbations","score":0.6869999766349792},{"id":"https://openalex.org/keywords/activity-limitation","display_name":"activity limitation","score":0.6449999809265137},{"id":"https://openalex.org/keywords/spain","display_name":"Spain","score":0.3319999873638153}],"concepts":[{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.8422999978065491},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7644000053405762},{"id":"https://openalex.org/C60229501","wikidata":"https://www.wikidata.org/wiki/Q18822","display_name":"Global Positioning System","level":2,"score":0.7544000148773193},{"id":"https://openalex.org/C26760741","wikidata":"https://www.wikidata.org/wiki/Q160402","display_name":"Perception","level":2,"score":0.5974000096321106},{"id":"https://openalex.org/C2777014857","wikidata":"https://www.wikidata.org/wiki/Q1383410","display_name":"Exacerbation","level":2,"score":0.5666000247001648},{"id":"https://openalex.org/C2775924081","wikidata":"https://www.wikidata.org/wiki/Q55608371","display_name":"Control (management)","level":2,"score":0.46970000863075256},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.361299991607666},{"id":"https://openalex.org/C2776473838","wikidata":"https://www.wikidata.org/wiki/Q174165","display_name":"Innovator","level":3,"score":0.3361999988555908},{"id":"https://openalex.org/C2778967200","wikidata":"https://www.wikidata.org/wiki/Q22813086","display_name":"Perceived control","level":2,"score":0.32690000534057617},{"id":"https://openalex.org/C2781318095","wikidata":"https://www.wikidata.org/wiki/Q33127638","display_name":"General practice","level":2,"score":0.3052000105381012},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.3025999963283539},{"id":"https://openalex.org/C2909082789","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma exacerbations","level":3,"score":0.296999990940094},{"id":"https://openalex.org/C3018080372","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma management","level":3,"score":0.28439998626708984},{"id":"https://openalex.org/C138816342","wikidata":"https://www.wikidata.org/wiki/Q189603","display_name":"Public health","level":2,"score":0.2815999984741211},{"id":"https://openalex.org/C545542383","wikidata":"https://www.wikidata.org/wiki/Q2751242","display_name":"Medical emergency","level":1,"score":0.2745000123977661}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2025.pa2461","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2461","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa2461","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3063792210","https://openalex.org/W2411204722","https://openalex.org/W3099645421","https://openalex.org/W4385503976","https://openalex.org/W2416855665","https://openalex.org/W2013648491","https://openalex.org/W7220159022","https://openalex.org/W2602099499","https://openalex.org/W2138343062","https://openalex.org/W2595288309"],"abstract_inverted_index":{"Aim:":[0],"ORIGEN":[1],"study":[2,39,43],"was":[3,40],"conducted":[4],"to":[5,24,64,155,227],"capture":[6],"general":[7],"physician\u2019s":[8],"(GP)":[9],"perception":[10,53],"about":[11],"symptom":[12,188],"control":[13,189,221],"in":[14,31,35,167,222],"asthma":[15,60,94,124,220],"patients":[16,58,81,92,106,171,224],"switched":[17,61],"from":[18,48,62,99,111,116,216],"innovator":[19],"Salmeterol/fluticasone":[20],"(Seretide\u00ae":[21],"pMDI;":[22,29],"SF-IN)":[23],"branded":[25,228],"generic":[26,229],"salmeterol/fluticasone":[27],"(Seroflo\u00ae":[28],"SF-BG)":[30],"routine":[32],"clinical":[33],"practice":[34],"Spain.":[36],"Method:":[37],"This":[38],"an":[41],"ecological":[42],"with":[44,59,93],"aggregated":[45],"data":[46],"collected":[47],"153":[49],"GPs":[50,74,88,122,132,163,175,178,215],"providing":[51],"their":[52,55,91,105,168,223],"of":[54,87,121,131,146,231],"last":[56,169],"5":[57,170],"SF-IN":[63],"SF-BG,":[65],"treated":[66],"between":[67],"3":[68],"and":[69,113,137],"6":[70],"months.":[71],"Results:":[72],"94%":[73],"had":[75],"public":[76],"practice;":[77],"74%":[78],"see":[79],"\u226510":[80],"per":[82],"week.":[83],"Post-switch,":[84],"the":[85,204,209],"number":[86,120],"who":[89,103,148,157],"perceived":[90,104],"as":[95,107],"well-controlled":[96],"increased":[97,152],"(67%":[98],"31%),":[100],"while":[101],"those":[102,147,156],"partially":[108],"controlled":[109],"(28%":[110],"45%)":[112],"uncontrolled":[114],"(5%":[115],"24%)":[117],"decreased.":[118],"Lesser":[119],"found":[123,164,179],"symptoms":[125],"post-switch.":[126,176],"Pre-switch,":[127],"a":[128],"similar":[129],"proportion":[130,145],"reported":[133,149],"stepping":[134,138,150],"down":[135,151],"(37%)":[136],"up":[139,159],"(39%)":[140],"patient":[141,200],"therapy.":[142],"However,":[143],"post-switch,":[144],"(48.5%),":[153],"compared":[154],"stepped":[158],"(22%).":[160],"Only":[161],"7%":[162],"no":[165,180],"exacerbation":[166],"pre-switch":[172,183],"vs":[173,184],"38%":[174],"13.5%":[177],"activity":[181],"limitation":[182],"post-switch":[185],"(39%).":[186],"Worsening":[187],"(41%),":[190],"device":[191],"misuse":[192],"(32%),":[193],"low":[194],"adherence":[195],"(25%),":[196],"economic/health":[197],"resources":[198],"(21%),":[199],"request":[201],"(8.5%)":[202],"were":[203],"key":[205],"reasons":[206],"for":[207],"switching":[208,226],"treatment.":[210],"Conclusion:":[211],"In":[212],"this":[213],"study,":[214],"Spain,":[217],"experienced":[218],"good":[219],"after":[225],"formulation":[230],"Salmeterol/Fluticasone.":[232]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-11-25T00:00:00"}